GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced today that it has entered into a warrant inducement agreement with an existing institutional investor. The agreement provides for the immediate exercise of existing warrants to purchase up to 5,697,628 shares of the company's common stock at an exercise price of $0.64 per share, generating gross cash proceeds of approximately $3,646,482 before deducting financial advisor fees and other transaction expenses. The company intends to use the net proceeds for working capital and other general corporate purposes.
In consideration for the immediate exercise of the existing warrants, the investor will receive new unregistered warrants in a private placement, allowing the purchase of up to 11,395,256 shares of common stock. These new warrants will have an exercise price of $0.64, will become exercisable upon shareholder approval of the issuance of the underlying shares, and will expire five years after that approval date. The closing of the transaction is expected to occur on or about August 27, 2026, subject to customary closing conditions.
The financing comes as GeoVax advances its priority program, GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is progressing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026 to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. The company is also developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity, which has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies.
This warrant inducement transaction is a strategic move to secure additional capital, which is essential for a clinical-stage biotech company that relies on external funding to support its research and development activities. The proceeds will likely be used to fund ongoing clinical trials, manufacturing scale-up, and other corporate expenses. For investors, this transaction provides an opportunity for the institutional investor to increase its position in the company, while the company gains immediate liquidity without the need for a traditional public offering, which could be dilutive to existing shareholders.
The private placement of the new warrants and underlying shares will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933 and Regulation D. As a result, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in this offering.
GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. The company's forward-looking statements highlight risks and uncertainties, including the ability to obtain acceptable clinical trial results, secure regulatory approvals, and raise required capital to complete development. The company undertakes no obligation to update these statements, except as required by law.
This transaction underscores the company's commitment to advancing its pipeline while managing its financial resources. By securing immediate capital, GeoVax aims to continue its mission of developing vaccines and immunotherapies for high-consequence infectious diseases and solid tumor cancers, potentially impacting global public health and biodefense preparedness.
